Prescriptions for controlled-release oxycodone, a narcotic analgesic, recently contributed to a dramatic increase in pharmacy costs for a large private insurance company. To determine whether this agent offered clinical benefits over other available drugs that would justify its significantly greater cost, a systematic review of 16 clinical trials was undertaken. The review suggested that immediate-release and controlled-release preparations of oxycodone have similar efficacy and comparable side effect profiles. Controlled-release oxycodone has the advantage of less frequent dosing than immediate-release oxycodone; however, other agents may be dosed infrequently at much lower costs. For patients requiring a controlled-release opioid treatment, controlledrelease morphine and methadone should be considered because they appear to be as effective as oxycodone and cost considerably less. Controlled-release oxycodone may be appropriate for some patients, particularly if they cannot tolerate other controlled-release or long-acting opioid analgesics. A recent study conducted within a large United States university-based health care system revealed that the greatest cost in caring for patients with low back pain arose from treatment with narcotic analgesics.
1, 2 From 1999-2001, a large private workers' compensation insurance company (Liberty Northwest Insurance Co., Portland, OR) experienced a sharp upturn in pharmacy costs that was largely attributable to prescriptions for controlled-release oxycodone for outpatient pain treatment. As a result, the recent literature was reviewed to determine whether controlled-release oxycodone offered clinical benefits over other available drugs that would justify its significantly greater cost.
Methods
An electronic search of the MEDLINE database from January 1994-October 2000 with the medical subject heading (MeSH) oxycodone yielded 69 citations. All clinical trials that addressed the safety and efficacy of oxycodone (immediate-or controlled-release) or the relative safety and efficacy of oxycodone compared with other opioids were selected. Of the 69 citations, 15 met the inclusion criteria as prospective or retrospective clinical trials; the remaining citations were reviews, editorials, letters, or otherwise inappropriate. An additional study that was cited by the manufacturer (Purdue Pharma L.P., Norwalk, CT) in its marketing materials was included in the analysis for a total of 16 clinical trials. 
Results

Safety and Efficacy of Oxycodone for Treatment of Noncancer Pain
Seven studies addressed the safety and efficacy of oxycodone for the treatment of noncancer pain (Table 1) . [4] [5] [6] [7] [8] [9] [10] All of these studies demonstrated that oxycodone and other opioid analgesics were effective for this indication. Oxycodone was superior to placebo in relieving self-reported pain. 6, 7, 10 Comparisons of oxycodone with nonsteroidal antiinflammatory drugs or other nonopioid treatments demonstrated that opioidtreated patients had superior pain relief. 4, 6, 9 However, comparisons of controlled-release oxycodone with immediate-release oxycodone showed no significant differences between the two formulations with regard to analgesic efficacy or side effect profiles. 5, 6, 8 These studies suggest that controlled-release oxycodone offered no clinically significant advantage over immediaterelease oxycodone in the management of noncancer pain.
Effect of Controlled-Release Oxycodone on Quality of Life in Patients with Noncancer Pain
Controlled-release oxycodone is effective in reducing chronic noncancer pain but is accompanied by significant adverse effects. Until recently, only surveys and open trials assessed the efficacy and safety of opioids for the treatment of noncancer pain. These studies had inconsistent results. 10, 11 Controlled-release oxycodone failed to demonstrate consistent benefit on quality of life, despite showing superiority over placebo in selfreported pain scores. 7, 10 Typical opioid adverse effects, such as constipation, nausea, vomiting, and somnolence, were more frequent and severe in the active treatment groups than in the placebo groups. In a trial evaluating 50 patients suffering from postherpetic neuralgia, global disability scores statistically favored active treatment. 10 However, because a nonvalidated assessment tool was used and the difference observed was quite small, the clinical relevance of this finding is difficult to determine. Furthermore, neither the Beck Depression Inventory nor the Profile of Mood States questionnaire detected differences in affective state and mood factors between the active treatment group and placebo group.
In a long-term experiment with 133 patients who experienced osteoarthritis pain, several parameters, including self-reported pain, were examined. 7 In addition to nonvalidated tests, the modified Stanford Health Assessment Questionnaire was used to assess the effect of controlled-release oxycodone on quality of life. In this study, active treatment did not improve quality of life. 7 These data suggest that treatment with controlled-release oxycodone does not improve quality of life in patients with chronic noncancer pain.
Safety and Efficacy of Immediate-Release versus Controlled-Release Oxycodone
Six studies compared the safety and efficacy of controlled-release oxycodone with immediaterelease oxycodone in cancer and noncancer pain (Table 2) . 5, 6, 8, [12] [13] [14] Only one of these studies found that the controlled-release formulation was superior to the immediate-release formulation in treating postoperative pain, with lower dosages, improved pain control, and fewer side effects. 14 The remaining five studies showed no significant differences in analgesic effect between immediate-release and controlled-release oxycodone. 5, 6, 8, 12, 13 Differences in specific adverse effects between controlled-release and immediate-release oxycodone were not consistent among trials. Adverse effects such as nausea, somnolence, dizziness, constipation, pruritus, and headache were reported in both treatment groups in all studies. 5, 6, 8, [12] [13] [14] In three trials, there was no statistically significant difference in adverse effects between controlled-release and immediate-release oxycodone. 5, 8, 13 However, in a trial conducted in 164 patients with cancer, the frequency of headache and gastrointestinal adverse effects was lower with controlled-release oxycodone than with immediate-release oxycodone. 12 In another trial conducted in 107 patients with osteoarthritis pain, nausea was reported less frequently by patients treated with the controlled-release product. 6 Thus, half of the studies comparing immediate-release oxycodone with the controlled-release formulation showed no significant difference in side effects. Controlled-release oxycodone has not demonstrated a consistent clinical benefit over immediate-release oxycodone.
Safety and Efficacy of Oxycodone Compared with Other Opioids
Five randomized, double-blind clinical trials compared the efficacy of controlled-release oxycodone with other long-acting opioids (Table  3) . 3, [15] [16] [17] [18] Four of them compared controlledrelease oxycodone with controlled-release morphine; no difference in analgesic efficacy between the two treatments was found. 3, 15, 16, 18 One study reported a higher frequency of itching and scratching with morphine than with oxycodone. 3 Another study showed a similar frequency of adverse effects with the two drugs, but vomiting was associated more frequently with controlled-release morphine, and constipation was associated more frequently with controlled-release oxycodone. 18 No increase in any one adverse effect was noted in these four trials. 3, 15, 16, 18 In a comparison of controlled-release oxycodone and hydromorphone, no difference in analgesic efficacy or adverse effects was observed. 17 These five studies suggest neither an advantage in analgesic efficacy nor a consistent significant decrease in adverse effects with controlled-release oxycodone versus controlledrelease morphine or controlled-release hydromorphone.
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Discussion
A review of the recent literature suggests that immediate-release and controlled-release oxycodone have similar efficacy in the treatment of noncancer pain. The two preparations are also comparable with regard to type and frequency of adverse effects. Controlled-release oxycodone offers the advantage of less frequent dosing than immediate-release oxycodone; however, other available preparations allow infrequent dosing at much lower costs (Table 4) . 19 Data demonstrated no significant clinical advantage for controlledrelease oxycodone over other controlled-release opioids, such as controlled-release morphine or controlled-release hydromorphone.
Equipotent dosages of controlled-release morphine and controlled-release oxycodone have not been clearly established, which makes a cost comparison difficult. In a single-dose study, . 19 This example is not intended to be used as a guide for equianalgesic dosing. . 19 This example is not intended to be used as a guide for equianalgesic dosing. controlled-release oxycodone was approximately twice as potent as controlled-release morphine. 16 However, in studies of longer duration, the difference in potency was smaller. 3, 15, 18 Using 2001 prices, a patient with chronic pain who receives MS Contin 100 mg twice/day would pay $328/month. 19 An approximately equianalgesic dosage (80 mg twice/day) of OxyContin would cost $462/month (Table 4) . 19 Although no published studies compare methadone with oxycodone, several reports suggest that methadone is an equally effective, less expensive alternative to controlled-release morphine and other narcotics. [20] [21] [22] [23] [24] Therefore, methadone should not be excluded as a possible alternative to controlled-release oxycodone. The pharmacokinetic and pharmacologic properties of methadone make it favorable for treating patients with chronic pain who require large amounts of narcotics. 24, 25 Methadone has a long and variable elimination half-life (up to 128 hrs) and good bioavailability. It is dispersible in solution for oral administration and acts as an Nmethyl-D-aspartate-receptor antagonist to reduce tolerance to opioids. 25 In addition, whereas the dose relationship between morphine and oxycodone is linear during long-term administration, the dose relationship between methadone and these compounds is nonlinear. At morphine dosages less than 100 mg/day, the conversion ratio for methadone is 3:1. At morphine dosages higher than 800 mg/day, the ratio increases to 15:1. 24, 25 Thus, the potential economic savings of methadone become disproportionately greater as patients require more narcotic (Figures 1 and 2) . The distinctive characteristics of methadone may complicate switching patients to this agent from other opioids; however, with close monitoring, appropriate patients can be safely switched. 23, 25 For patients requiring controlled-release opiates, methadone and controlled-release morphine are established treatments for chronic pain and are less expensive alternatives to controlled-release oxycodone.
Conclusions
Immediate-release and controlled-release oxycodone are equally effective in the treatment of pain and have similar adverse effect profiles. Controlled-release preparations and products with a long duration of action are attractive because they offer the advantage of longer dosing intervals, which results in sustained analgesic effect and greater convenience. The reviewed literature suggests no clinically significant advantage of controlled-release oxycodone over other long-acting opioids to justify its greater cost.
If a patient is an appropriate candidate for a controlled-release opioid, controlled-release morphine and methadone should be considered because they appear to be equally effective and cost considerably less than oxycodone. Controlled-release oxycodone may be appropriate for some patients, particularly if they cannot tolerate other controlled-release or longacting opioid analgesics.
